StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a research note issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Stock Performance
Shares of NASDAQ:AEZS opened at $2.19 on Friday. The company has a market cap of $10.64 million, a P/E ratio of -0.46 and a beta of 1.56. Aeterna Zentaris has a one year low of $1.36 and a one year high of $3.38. The business’s 50-day simple moving average is $1.90 and its 200 day simple moving average is $1.95.
Aeterna Zentaris Company Profile
Featured Articles
- Five stocks we like better than Aeterna Zentaris
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Overbought Stocks Explained: Should You Trade Them?
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What Are Trending Stocks? Trending Stocks Explained
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.